ZYBT
Zhengye Biotechnology Holding Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CN
$1.37
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -23.5%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -86.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025